Cognitive function in schizophrenia deficits, functional consequences, and future treatment

Psychiatric Clinics of North America

Volumn 26, Issue 1, 2003, Pages 25-40

  Sharma, Tonmoy ^a   Antonova, Lena ^b  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; HISTAMINE H1 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN 6 RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR;

ATTENTION; BRAIN FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; EMPLOYMENT; HUMAN; INFORMATION PROCESSING; INTELLIGENCE QUOTIENT; LEARNING; MEMORY; MENTAL DISEASE; NEUROTRANSMISSION; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROBLEM SOLVING; PSYCHOMETRY; PSYCHOPHARMACOLOGY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SOCIAL INTERACTION; TASK PERFORMANCE; WORKING MEMORY;

ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; HUMANS; NEUROPSYCHOLOGICAL TESTS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 0037349471     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0193-953X(02)00084-9     Document Type: Review

References (82)

1. Hegarty JD, Baldessarini RJ, Tohen M, et al. One hundred years of schizophrenia: a metaanalysis of the outcome literature. Am J Psychiatry 1994;151:1409-16.
2. Capri S. Methods for evaluation of the direct and indirect costs of long-term schizophrenia. Acta Psychiatr Scand 1994;382(Suppl):80-3.
3. Torrey EF. Surviving schizophrenia: A manual for families, consumers and providers. New York: Harper Collins; 2002. p. 409.
4. Knapp M. Costs of schizophrenia. Br J Psychiatry 1997;171:509-18.
5. Kenny JT, Meltzer HY. Attention and higher cortical functions in schizophrenia. J Neuropsychiatry Clin Neurosci 1991;3:269-75.
6. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153:321-30.
7. Crow TJ, Done DJ, Sacker A. Childhood precursors of psychosis as clues to its evolutionary origins. Eur Arch Psychiatry Clin Neurosci 1995;245:61-9.
8. Friedman JI, Harvey PD, Coleman T, et al. Six-year follow-up study of cognitive and functional status across the lifespan in schizophrenia: a comparison with Alzheimer's disease and normal aging. Am J Psychiatry 2001;158:1441-8.
9. Heaton RK. Wisconsin Card Sorting Test. Psychological Assessment Resources; 1993.
10. Harvey PD, Lombardi J, Leibman M, et al. Cognitive impairment and negative symptoms in geriatric chronic schizophrenic patients: a follow-up study. Schizophr Res 1996;22:223-31.
11. Hughes C, Kumari V, Soni W, et al. Longitudinal study of symptoms and cognitive function in chronic schizophrenia. Schizophr Res 2002 (in press).
12. Bilder RM, Bogerts B, Ashtari M, et al. Anterior hippocampal volume reductions predict frontal lobe dysfunction in first episode schizophrenia. Schizophr Res 1995;17:47-58.
13. Bilder RM, Lipschutz-Broch L, Reiter G, et al. Intellectual deficits in first-episode schizophrenia: evidence for progressive deterioration. Schizophr Bull 1992;18:437-48.
14. Riley EM, McGovern D, Mockler D, et al. Neuropsychological functioning in first-episode psychosis - evidence of specific deficits. Schizophr Res 1999;43:47-55.
15. Green MF, Kern RS, Braff DL, et al. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull 2000;26:119-36.
16. Goldman-Rakic PS. Working memory dysfunction in schizophrenia. J Neuropsychiatry Clin Neurosci 1994;6:348-57.
17. Buchsbaum MS, Hazlett EA. Positron emission tomography studies of abnormal glucose metabolism in schizophrenia. Schizophr Bull 1998;24:343-64.
18. Stuss DT, Kaplan EF, Benson DF, et al. Evidence for the involvement of orbitofrontal cortex in memory functions: an interference effect. J Comp Physiol Psychol 1982;96:913-25.
19. Keefe RS, Roitman SE, Harvey PD, et al. A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia. Schizophr Res 1995;17:25-33.
20. Bressi S, Miele L, Bressi C, et al. Deficits of central executive component of working memory in schizophrenia. New Trends Exp Clin Psychiatry 1996;12:243-52.
21. Gold JM, Carpenter C, Randolph C, et al. Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch Gen Psychiatry 1997;54:159-65.
22. Pantelis C, Barnes TR, Nelson HE, et al. Frontal-striatal cognitive deficits in patients with chronic schizophrenia. Brain 1997;120:1823-43.
23. Sullivan EV, Shear PK, Zipursky RB, et al. Patterns of content, contextual, and working memory impairments in schizophrenia and nonamnesic alcoholism. Neuropsychology 1997;11:195-206.
24. Stone M, Gabrieli JDE, Stebbins T, et al. Working and strategic memory deficits in schizophrenia. Neuropsychology 1998;12:278-88.
25. Spitzer M. The psychopathology, neuropsychology, and neurobiology of associative and working memory in schizophrenia. Eur Arch Psychiatry Clin Neurosci 1993;243:57-70.
26. Rochester SR. Are language disorder in acute schizophrenia actually information processing problems? J Psychiatry Res 1978;14:275-83.
27. Cummings JL. Frontal-subcortical circuits and human behavior. Arch Neurol 1993;50:873-80.
28. Retain RM, Wolfson D. The Halstead-Reitan Neuropsychological test battery: theory and clinical interpretation. South Tucson, AZ: Neuropsychology Press; 1985.
29. Goldberg TE, Saint-Cry JA, Weinberger DR. Assessment of procedural learning and problem solving in schizophrenia patients by Tower of Hanoi type tasks. J Neuropsychiatry Clin Neurosci 1990;2:165-73.
30. Braff DL, Heaton R, Kuck J, et al. The generalized pattern of neuropsychological deficits in outpatients with chronic schizophrenia with heterogeneous Wisconsin Card Sorting Test results. Arch Gen Psychiatry 1991;48:891-8.
31. Morris RG, Rushe T, Woodruffe PW, Murray RM. Problem solving in schizophrenia: a specific deficit in planning ability. Schizophr Res 1995;14:235-46.
32. Voruganti LN, Heslegrave RJ, Awad AG. Neurocognitive correlates of positive and negative syndromes in schizophrenia. Can J Psychiatry 1997;42:1066-71.
33. Young DA, Davila R, Scher H. Unawareness of illness and neuropsychological performance in chronic schizophrenia. Schizophr Res 1993;10:117-24.
34. Garavan J, Browne S, Gervin M, et al. Compliance with neuroleptic medication in outpatients with schizophrenia: relationship to subjective response to neuroleptics; attitudes to medication and insight. Compr Psychiatry 1998;39:215-9.
35. Meltzer HY. Treatment of suicidality in schizophrenia. Ann N Y Acad Sci 2001;932:44-58.
36. Arango C, Calcedo BA, Gonzalez S, et al. Violence in inpatients with schizophrenia: a prospective study. Schizophr Bull 1999;25:493-503.
37. Hemsley DR. Schizophrenia. A cognitive model and its implications for psychological intervention. Behav Modif 1996;20:139-69.
38. Braff DL. Information processing and attention dysfunctions in schizophrenia. Schizophr Bull 1993;19:233-59.
39. Nuechterlein KH. Childhood precursors of adult schizophrenia. J Child Psychol Psychiatry 1986;27:133-44.
40. Cornblatt BA, Erlenmeyer-Kimling L. Global attentional deviance as a marker of risk for schizophrenia: specificity and predictive validity. J Abnorm Psychol 1985;94:470-8.
41. Trestman RL, Keefe RS, Mitropoulou V, et al. Cognitive function and biological correlates of cognitive performance in schizotypal personality disorder. Psychiatr Res 1995;59:127-36.
42. Cornblatt BA, Lenzenweger MF, Dworkin RH, et al. Positive and negative schizophrenic symptoms, attention, and information processing. Schizophr Bull 1985;11:397-408.
43. Ross DE, Thaker GK, Buchanan RW, et al. Eye tracking disorder in schizophrenia is characterized by specific ocular motor defects and is associated with the deficit syndrome. Biol Psychiatry 1997;42:781-96.
44. Perry W, Braff DL. Information-processing deficits and thought disorder in schizophrenia. Am J Psychiatry 1994;151:363-7.
45. Tulving E. Elements of episodic memory. New York: Academic Press; 1983.
46. Gold JM, Randolf C, Carpenter C, et al. Forms of memory failure in schizophrenia. J Abnorm Psychol 1992;101:487-94.
47. Saykin AJ, Gur RC, Gur RE, et al. Neuropsychological function in schizophrenia: selective impairment in memory and learning. Arch Gen Psychiatry 1991;48:618-24.
48. Saykin AJ, Shtasel DL, Gur RE, et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry 1994;51:124-31.
49. Paulsen JS, Heaton RK, Sadek JR, et al. The nature of learning and memory impairments in schizophrenia. J Int Neuropsychol Soc 1995;1:88-99.
50. Kareken DA, Moberg PJ, Gur RC. Proactive inhibition and semantic organization: relationship with verbal memory in patients with schizophrenia. J Int Neuropsychol Soc 1996;2:486-93.
51. Goldman-Rakic PS. Working memory dysfunction in schizophrenia. J Neuropsychiatry Clin Neurosci 1994;6:348-57.
52. McKay AP, McKenna PJ, Bentham P, et al. Semantic memory is impaired in schizophrenia. Biol Psychiatry 1996;39:929-37.
53. Aloia MS, Gourovitch ML, Missar D, et al. Cognitive substrates of thought disorder: II. specifying a candidate cognitive mechanism. Am J Psychiatry 1998;155:1677-84.
54. Goldberg TE, Aloia MS, Gourovitch ML, et al. Cognitive substrates of thought disorder: I. the semantic system. Am J Psychiatry 1998;155:1671-6.
55. Schmand B, Brand N, Kuipers T. Procedural learning of cognitive and motor skills in psychotic patients. Schizophr Res 1992;8:157-70.
56. Kumari V, Corr PJ, Mulligan OF, et al. Effects of acute administration of d-amphetamine and haloperidol on procedural learning in man. Psychopharmacology (Berl) 1997;129:271-6.
57. Bedard MA, Scherer H, Stip E, et al. Procedural learning in schizophrenia: further consideration on the deleterious effect of neuroleptics. Brain Cogn 2000;43:31-9.
58. Nanko S, Moridaira J. Reproductive rates in schizophrenic outpatients. Acta Psychiatr Scand 1993;87:400-4.
59. Lehman AF, Goldberg R, Dixon LB, et al. Improving employment outcomes for persons with severe mental illnesses. Arch Gen Psychiatry 2002;59:165-72.
60. Scott J. Homelessness and mental illness. Br J Psychiatry 1993;162:314-24.
61. Liddle PF. Cognitive impairment in schizophrenia: its impact on social functioning. Acta Psychiatr Scand 2000;400(Suppl):11-6.
62. Mueser KT. Cognitive functioning, social adjustment and long-term outcome in schizophrenia. In: Sharma T, Harvey P, editors. Cognition in schizophrenia. Cambridge: Oxford University Press; 2000. p. 157-77.
63. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999;25:233-55.
64. King DJ. The effect of neuroleptics on cognitive and psychomotor function. Br J Psychiatry 1990;157:799-811.
65. Strauss ME, Reynolds KS, Jayaram G, et al. Effects of anticholinergic medication on memory in schizophrenia. Schizophr Res 1990;3:127-9.
66. Keefe RS, Silva SG, Perkins DO, et al. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999;25:201-22.
67. Sharma T. Cognitive effects of conventional and atypical antipsychotics in schizophrenia. Br J Psychiatry 1999;38:44-51.
68. Hagger C, Buckley P, Kenny JT, et al. Improvement in cognitive functions and psychiatric symptoms in treatment - refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993;34:702-12.
69. Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 1994;36:717-25.
70. Grace J, Bellus SB, Raulin ML, et al. Long-term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning. Psychiatr Serv 1996;47:41-5.
71. Galletly CA, Clark CR, McFarlane AC, et al. Relationships between changes in symptom ratings, neurophysiological test performance and quality of life in schizophrenic patients treated with clozapine. Psychiatry Res 1997;72:161-6.
72. Goldberg TE, Greenberg RD, Griffin SJ, et al. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 1993;162:43-8.
73. Cuesta MJ, Peralta V, Zarzuela A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr Res 2001;48:17-28.
74. Purdon SE, Malla A, Labelle A, et al. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 2001;26:137-49.
75. Velligan DI, Miller AL. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment. J Clin Psychiatry 1999;60(Suppl 23):25-8.
76. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998;18:63-101.
77. Ellenbroek BA, Cools AR. Animal models for the negative symptoms of schizophrenia. Behav Pharmacol 2000;11:223-33.
78. Friedman JI, Temporini H, Davis KL. Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry 1999;45:1-6.
79. Heaton RK, Crowley TJ. Effect of psychiatric disorders and their somatic treatments on neuropsychological test results. In: Filskov S, Boll TJ, editors. Handbook of clinical neuropsychology. New York: John Wiley & Sons; 1981. p. 481-525.
80. Kern RS, Green MF, Marshall BD, et al. Risperidone versus haloperidol on secondary memory: can newer medications aid learning? Schizophr Bull 1999;25:223-32.
81. Stripp E, Lussier I. The effect of risperidone on cognition in patients with schizophrenia. Can J Psychiatry 1996;41:35-40.
82. Sharma T. Quetiapine - efficacy in different domains. Eur Neuropsychopharmacol 2001;11(Suppl 4):S385-90.